Pocket Guide to GASTROINTESTINAL DRUGS Edited by M
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Granisetron "Vianex"
EU‐RISK MANAGEMENT PLAN GRANISETRON VIANEX® 1 MG/ML, SOLUTION FOR INJECTION/ INFUSION precautionary measure, breast‐feeding should not be advised during treatment with Granisetron “Vianex”. Legal Status: Prescription only product. VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nausea and vomiting associated with chemotherapy and radiotheraphy: One of the most distressing symptoms for patients undergoing both surgery and chemotherapy is nausea and vomiting. These symptoms have a significant impact on quality of life and can lead to malnutrition, inability to respond to treatment and an increased length of hospitalization. Emesis is more commonly associated with chemotherapeutic agents; however, radiation‐induced nausea and vomiting (RINV) can affect a significant proportion of patients, depending on the treated area, dose fractionation, and volume of radiotherapy. The relative risk for developing nausea and vomiting with chemotherapy ranges from 30 to 90% and is dependent upon the chemotherapeutic agent used. Relative risk for nausea and vomiting with radiation therapy is approximately 40%.2,3,4,5 Post‐operative nausea and vomiting Postoperative nausea and vomiting (PONV) is a major source of patient dissatisfaction and is the leading cause of discharge delays and unanticipated postsurgical hospital admissions. In the absence of pharmacological treatment, the rate of PONV is approximately 30% in general population, and can be as high as 70% in patients at highest risk. Several risk factors as surgery type, female gender, non‐smoker status, history of postoperative nausea and vomiting or motion sickness and post‐operative opioid use have been acknowledged. Additionally, post‐ operative vomiting (POV) occurs twice as frequently in children as in adults, increasing until puberty and then decreasing to adult incidence rates. -
Therapeutic Class Overview Irritable Bowel Syndrome Agents
Therapeutic Class Overview Irritable Bowel Syndrome Agents Therapeutic Class Overview/Summary: This review will focus on agents used for the treatment of Irritable Bowel Syndrome (IBS).1-5 IBS is a gastrointestinal syndrome characterized primarily by non-specific chronic abdominal pain, usually described as a cramp-like sensation, and abnormal bowel habits, either constipation or diarrhea, in which there is no organic cause. Other common gastrointestinal symptoms may include gastroesophageal reflux, dysphagia, early satiety, intermittent dyspepsia and nausea. Patients may also experience a wide range of non-gastrointestinal symptoms. Some notable examples include sexual dysfunction, dysmenorrhea, dyspareunia, increased urinary frequency/urgency and fibromyalgia-like symptoms.6 IBS is defined by one of four subtypes. IBS with constipation (IBS-C) is the presence of hard or lumpy stools with ≥25% of bowel movements and loose or watery stools with <25% of bowel movements. When IBS is associated with diarrhea (IBS-D) loose or watery stools are present with ≥25% of bowel movements and hard or lumpy stools are present with <25% of bowel movements. Mixed IBS (IBS-M) is defined as the presence of hard or lumpy stools with ≥25% and loose or water stools with ≥25% of bowel movements. Final subtype, or unsubtyped, is all other cases of IBS that do not fall into the other classes. Pharmacological therapy for IBS depends on subtype.7 While several over-the-counter or off-label prescription agents are used for the treatment of IBS, there are currently only two agents approved by the Food and Drug Administration (FDA) for the treatment of IBS-C and three agents approved by the FDA for IBS-D. -
Novel Formulations for Treatment of Migraine
(19) TZZ _T (11) EP 2 756 756 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.07.2014 Bulletin 2014/30 A01N 43/42 (2006.01) A61K 31/44 (2006.01) (21) Application number: 14165112.5 (22) Date of filing: 24.04.2009 (84) Designated Contracting States: • Turanin, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Emeryville, CA California 94608 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Hawley, Roger PT RO SE SI SK TR Emeryville, CA California 94608 (US) • Schuster, Jeffrey, A. (30) Priority: 28.04.2008 US 48463 Bolinas, CA California 94924 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Duxbury, Stephen et al accordance with Art. 76 EPC: Arnold & Siedsma 09739139.5 / 2 273 880 Pettenkoferstrasse 37 80336 München (DE) (71) Applicant: Zogenix, Inc. Emeryville CA 94608 (US) Remarks: This application was filed on 17-04-2014 as a (72) Inventors: divisional application to the application mentioned • Farr, Stephen J. under INID code 62. Orinda, CA California 94563 (US) (54) Novel formulations for treatment of migraine (57) Systems and methods are described for treating Systems that are self contained, portable, prefilled, and un-met medical needs in migraine and related conditions simple to self administer at the onset of a migraine attack such as cluster headache. Included are treatments that are disclosed, and preferably include a needle-free in- are both rapid onset and long acting, which include sus- jector and a high viscosity formulation, to eliminate such tained release formulations, and combination products, issues as fear of self administration with needles, and Also included are treatments for multiple symptoms of needle stick and cross contamination. -
1Hol=C2 Light Water (C2 > C1) Patent Application Publication May 1, 2008 US 2008/O103092 A1 5 (1H2O=C2
US 20080 103092A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0103092 A1 Pomytkin et al. (43) Pub. Date: May 1, 2008 (54) METHODS FOR INTRADERMAL, Publication Classification TRANSIDERMAL, ORTRANSMUCOSAL DELIVERY OF BIOLOGICALLY ACTIVE (51) Int. Cl. SUBSTANCES A6II 47/02 (2006.01) A6II 38/02 (2006.01) (76) Inventors: Igor Anatolievich Pomytkin, Moscow A6IR 48/00 (2006.01) (RU); Sergey Pavlovich Soloviev, (52) U.S. Cl. .................................... 514/8: 514/2: 514/769 Moscow (RU) (57) ABSTRACT Correspondence Address: NOTARO AND MICHALOS This invention relates to method for intradermal, transdermal 1OO DUTCH HILL ROAD or transmucosal delivering a biologically active Substance to a mammal in need thereof, which method comprises a step of SUTE 110 co-administering to said mammal with the biologically active ORANGEBURG, NY 10962-2100 (US) Substance an effective amount of an absorption enhancer, which is water comprising from about 99.760 to about 10 (21) Appl. No.: 11/817,919 99.999% of light isotopologue H, 0 and up to 100% of residual isotopologues H, '70, H., '80, HH'0, HH'70, (22) PCT Filed: Mar. 11, 2005 'HH'0, H, O, H, '70, and H 0. Such biologically (86) PCT NO.: PCT/RUOS/OO108 active substance is selected from the group consisting of drugs, physiologically active peptides, physiologically active S371(c)(1), proteins, glycoproteins, nucleic acid, nutrients, vitamins, and (2), (4) Date: Nov. 15, 2007 minerals. 5 1Hol=C2 Light Water (C2 > C1) Patent Application Publication May 1, 2008 US 2008/O103092 A1 5 (1H2O=C2 Light Water (C2 > C1) Licuid US 2008/O 103092 A1 May 1, 2008 METHODS FOR INTRADERMAL, TRANSDERMAL wherein the level of light water isotopologue 'H'Ois about ORTRANSMUCOSAL DELIVERY OF 99.7317% (Vienna Standard Mean Ocean Water, VSMOW), BIOLOGICALLY ACTIVE SUBSTANCES and wherein total level of all eight heavy isotopologues com prising at least one heavy isotopes H, O, and 'O is about TECHNICAL FIELD 0.2683% (e.g. -
Antihypotensive Agent Disrupts the Immune System in Sepsis 12 June 2020
Antihypotensive agent disrupts the immune system in sepsis 12 June 2020 Patients who go into septic shock are treated with with endotoxin, a bacterial cell-wall component. If the antihypotensive agent norepinephrine. mice were administered norepinephrine, their Researchers from Radboud University Medical immune response was strongly suppressed." Center published results in today's American Journal of Respiratory and Critical Care Medicine Furthermore, in mice with an actual bacterial revealing that its use is not without drawbacks: The infection, infusion of norepinephrine led to drug disrupts the immune system and increases increased bacterial growth in the spleen, liver, and susceptibility to infections. This may have negative blood, again indicating a weakened immune consequences for patients. Research into system. "We also studied the effect of vasopressin, alternatives is therefore justified. an alternative antihypotensive agent, on white blood cells and mice," Stolk says. "Interestingly, in Sepsis is a life-threatening inflammatory response contrast to norepinephrine, this drug has no effects spreading throughout the body due to an infection. on the immune system or defense against One in four patients with sepsis succumbs to it, infections." and it is the No. 1 cause of death around the globe. As such, sepsis was recently designated as Healthy volunteers a global health priority by the World Health Organization (WHO). Patients with sepsis have a "Next, we wanted to know whether the effects of severely dysregulated immune system, which norepinephrine also apply to humans," said Matthijs impairs clearance of the infection and leaves the Kox, head of the study. "We infused either body susceptible to new infections with an norepinephrine, vasopressin, or a placebo in three increased risk of death. -
5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor -
Gastroparesis: 2014
GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2. -
8-GI Drugs Final
Gastrointestinal Drugs Subcommittee: Prozialeck, Walter (Chair) [email protected] Escher, Emanuel [email protected] Garrison, James C. [email protected] Henry, Matthew, [email protected] Weber, Donna R [email protected] Recommended Curriculum Equivalent: 1.5 h Acid Reducers and Drugs for the Treatment of Peptic Ulcer Disease Proton pump inhibitors First generation Second generation OMEPRAZOLE ESOMEPRAZOLE LANSOPRAZOLE PANTOPRAZOLE RABEPRAZOLE Learning Objectives Physiology and pathophysiology Describe the synthesis and mechanism of H+ secretion by the parietal cells Mechanism of action Describe the mechanism of action of proton pump inhibitors and why they are selective for the parietal cell proton pump. Actions on organ systems Describe the pharmacological effects of the drugs on gastric function. Are there effects on other organ systems? Pharmacokinetics Describe the pharmacokinetics of proton pump inhibitors? Are there significant differences among the different drugs in this class? Adverse effects, drug interactions and contraindications Describe the principal adverse effects of proton pump inhibitors. Describe the clinically important drug interactions of proton pump inhibitors. Describe the principal contraindications of proton pump inhibitors. Therapeutic uses Describe the current therapeutic uses of proton pump inhibitors. 1 Clinical Pharmacology Omeprazole is perceived to be the most potent of this drug class in inhibiting CYP2C19 activity and is proposed to have potential drug interactions with other drugs metabolized by this P450 isoform. Concern has been raised about potential inhibition of clopidogrel activation in patients taking both drugs concurrently. Current consensus is that in such patients clopidogrel with pantoprazole may be a safer choice to reduce the probability of a drug interaction involving CYP2C19. -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Midodrine Hydrochloride Tablets, USP Rx Only
MIDODRINE HCL- midodrine hydrochloride tablet Eon Labs, Inc. ---------- Midodrine Hydrochloride Tablets, USP Rx Only WARNING Because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure, it should be used in patients whose lives are considerably impaired despite standard clinical care. The indication for use of midodrine hydrochloride tablets in the treatment of symptomatic orthostatic hypotension is based primarily on a change in a surrogate marker of effectiveness, an increase in systolic blood pressure measured one minute after standing, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, principally improved ability to carry out activities of daily living, have not been verified. DESCRIPTION Midodrine hydrochloride is a vasopressor/antihypotensive agent. Midodrine hydrochloride is an odorless, white, crystalline powder, soluble in water and sparingly soluble in methanol having a pKa of 7.8 (0.3% aqueous solution), a pH of 3.5 to 5.5 (5% aqueous solution) and a melting range of 200°C to 203°C. It is chemically described as: (1) Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2- hydroxyethyl]-monohydrochloride, (±)-; or (2) (±)-2-amino-N-(ß-hydroxy-2,5- dimethoxyphenethyl)acetamide monohydrochloride. Midodrine hydrochloride’s molecular formula is C12H18N2O4HCl, its molecular weight is 290.7 and its structural formula is: Each tablet for oral administration contains 2.5 mg, 5 mg or 10 mg of midodrine hydrochloride and the following inactive ingredients: pregelatinized starch (corn starch), microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate. In addition, the 5 mg tablets contain FD&C yellow No. -
CISAPRIDE (Veterinary—Systemic)
CISAPRIDE (Veterinary—Systemic) There are no human- or veterinary-labeled commercial ELUS,CANDelayed gastric emptying (treatment)EL; or cisapride products in the United States or Canada. ELUS,CANSmall bowel motility disorders (treatment)EL— Although no feline studies are available, the Category: Gastrointestinal emptying adjunct; documented effects of cisapride in healthy dogs and peristaltic stimulant. other animals suggest it may have efficacy in disorders that benefit from stimulation of gastric, Indications small intestinal, or colonic motility and from Note: Cisapride is not specifically approved for shortened transit time in cats (Evidence rating: B- {R-2; 4-7; 21-24} veterinary use. In other USP information 2). monographs, the ELUS and ELCAN designations refer to uses that are not included in U.S. and Canadian Dogs product labeling; however, in this monograph Potentially effective they reflect the lack of commercial product ELUS,CANGastroesophageal reflux (treatment)EL; availability in the countries indicated. See also the ELUS,CANDelayed gastric emptying (treatment)EL; Regulatory Considerations section below in this ELUS,CANSmall bowel motility disorders (treatment)EL; or monograph. US,CAN EL Colonic motility disorders (treatment)EL — Classification as Accepted, Potentially effective, Although no studies of clinical disease states are or Unaccepted is an evaluation of reasonable use available, studies of the effects of cisapride in that considers clinical circumstances, including healthy dogs suggest it may have efficacy in the availability of other therapies. The quality of disorders that benefit from stimulation of gastric, evidence reviewed for an indication is shown by small intestinal, or colonic motility and from the evidence rating. shortened transit time (Evidence rating: B-2 [table 1][table 2][table3]).{R-4-7; 17; 21-24} Cats Accepted Note: There is no evidence that cisapride is effective in ELUS,CAN EL Constipation, chronic (treatment) ; or the treatment of megaesophagus in dogs. -
Investigating the Pharmacology of Novel 5-HT3 Receptor Ligands; with the Potential to Treat Neuropsychiatric and Gastrointestinal Disorders
Investigating the pharmacology of novel 5-HT3 receptor ligands; with the potential to treat neuropsychiatric and gastrointestinal disorders by Alexander Roberts A thesis submitted to the University of Birmingham for the Degree of Doctor of Philosophy Institute of Clinical Sciences College of Medical and Dental Sciences University of Birmingham February 2020 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. Abstract The 5-hydroxytryptamine (5-HT; serotonin) 5-HT3 receptor is an excitatory ligand- gated ion channel expressed in for example the brain and the gastrointestinal tract. Two major subtypes of the receptor have been studied in the most detail; the homomeric 5-HT3A receptor and the heteromeric 5-HT3AB receptor. 5-HT3 receptor antagonists are used clinically to treat chemotherapy induced and post-operative nausea and vomiting, and demonstrate symptomatic relief in diarrhoea-predominant irritable bowel syndrome (IBS-d); but unfortunately, these medications cause adverse effects such as constipation or rarely ischemic colitis in the latter condition. This study has characterised the pharmacology of two structurally distinct 5-HT3 receptor partial agonists (vortioxetine and CSTI-300); and identified the unique binding properties of the cryptic orthosteric modulator 5-chloroindole (Cl-indole) for the human (h) 5-HT3 receptor.